Entrada Therapeutics, Inc.
TRDA
$8.33
-$0.76-8.36%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 37.40M | 19.57M | 94.69M | 59.12M | 41.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 37.40M | 19.57M | 94.69M | 59.12M | 41.85M |
| Cost of Revenue | 33.41M | 31.26M | 32.04M | 28.61M | 28.29M |
| Gross Profit | 3.99M | -11.69M | 62.66M | 30.51M | 13.56M |
| SG&A Expenses | 9.86M | 9.97M | 9.24M | 9.40M | 8.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.27M | 41.23M | 41.27M | 38.01M | 36.94M |
| Operating Income | -5.87M | -21.66M | 53.42M | 21.11M | 4.91M |
| Income Before Tax | -739.00K | -15.89M | 57.79M | 25.33M | 9.20M |
| Income Tax Expenses | -1.87M | -1.86M | 2.76M | 1.83M | 18.74M |
| Earnings from Continuing Operations | 1.13M | -14.03M | 55.03M | 23.50M | -9.54M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 1.13M | -14.03M | 55.03M | 23.50M | -9.54M |
| EBIT | -5.87M | -21.66M | 53.42M | 21.11M | 4.91M |
| EBITDA | -4.88M | -20.72M | 54.33M | 22.05M | 5.64M |
| EPS Basic | 0.03 | -0.35 | 1.61 | 0.70 | -0.29 |
| Normalized Basic EPS | -0.01 | -0.24 | 1.06 | 0.47 | 0.17 |
| EPS Diluted | 0.02 | -0.35 | 1.55 | 0.68 | -0.29 |
| Normalized Diluted EPS | -0.01 | -0.24 | 1.02 | 0.46 | 0.17 |
| Average Basic Shares Outstanding | 40.84M | 40.63M | 34.18M | 33.50M | 33.37M |
| Average Diluted Shares Outstanding | 43.05M | 40.63M | 35.51M | 34.79M | 33.37M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |